Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine

• Published in: Biomedicine & pharmacotherapy 2024-06, Vol.175, p.116776, Article 116776
• Main Authors: Chen, XiRui, Liu, SiWei, Chen, MoXin, Ni, Ni, Zhou, Rong, Wang, YiQi, Xu, Yang, Wang, YuanHui, Gao, HuiQin, Zhang, DanDan, Tang, ZhiMin, Shu, Qin, Zhang, Jing, Li, Lin, Ju, YaHan, Gu, Ping
• Format: Article
• Language: English
• Subjects: 2-deoxy-D-glucose; Animals; Choroidal neovascularization; Choroidal Neovascularization - drug therapy; Choroidal Neovascularization - metabolism; Choroidal Neovascularization - pathology; Deoxyglucose - administration & dosage; Deoxyglucose - pharmacology; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Human Umbilical Vein Endothelial Cells - drug effects; Human Umbilical Vein Endothelial Cells - metabolism; Humans; Liposomes; Mice; Mice, Inbred C57BL; N-glycosylation; Nanoliposome; Nanomedicine - methods; Oligopeptides - chemistry; RGD; Vascular Endothelial Growth Factor Receptor-2 - metabolism; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - metabolism
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.116776

Choroidal neovascularization (CNV), characterized as a prominent feature of wet age-related macular degeneration (AMD), is a primary contributor to visual impairment and severe vision loss globally, while the prevailing treatments are often unsatisfactory. The development of conventional treatment strategies has largely been based on the understanding that the angiogenic switch of endothelial cells is dictated by angiogenic growth factors alone. Even though treatments targeting vascular endothelial growth factor (VEGF), like Ranibizumab, are widely administered, more than half of the patients still exhibit inadequate or null responses, emphasizing the imperative need for solutions to this problem. Here, aiming to explore therapeutic strategies from a novel perspective of endothelial cell metabolism, a biocompatible nanomedicine delivery system is constructed by loading RGD peptide-modified liposomes with 2-deoxy-D-glucose (RGD@LP-2-DG). RGD@LP-2-DG displayed good targeting performance towards endothelial cells and excellent in vitro and in vivo inhibitory effects on neovascularization were demonstrated. Moreover, our mechanistic studies revealed that 2-DG interfered with N-glycosylation, leading to the inhibition of vascular endothelial growth factor receptor 2 (VEGFR2) and its downstream signaling. Notably, the remarkable inhibitory effect on neovascularization and biocompatibility of RGD@LP-2-DG render it a highly promising and clinically translatable therapeutic candidate for the treatment of wet AMD and other angiogenic diseases, particularly in patients who are unresponsive to currently available treatments. [Display omitted] •Targeting endothelial cell metabolism provides a novel therapeutic strategy for wet AMD.•Intravitreal injections of 2-DG inhibit choroidal neovascularization.•RGD-modified liposomes enhance cellular uptake and CNV lesion targeting.•RGD@LP-2-DG exhibits potent anti-angiogenic effects in vitro and in vivo.•RGD@LP-2-DG is a promising therapeutic for wet AMD and other angiogenic diseases.